Patent · US Expired

Mage-A3 peptides presented by HLA class molecules

US6716809B1 · kind B1 · utility

6Cited by

5References

14Claims

0Family size

Assignee

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

Erwin Schultz · Erlangen, DE
Pascal Chaux · Brussels, BE
Jacques Van Snick · Brussels, BE
Bernard Lethe · Brussels, BE
Thierry Boon-Fallaur · Brussels, BE
Pierre van der Bruggan · Brussels, BE
Vincent Stroobant · Brussels, BE
Kris Thielemans · Wilrijk, BE
Jurgen Corthals · Brussels, BE
Carlo Heirman · Dendermonde, BE

Key dates

Filing date	Sep 15, 1999
Grant date	Apr 6, 2004
Priority date	—
Expiry date	Sep 15, 2019

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.